Baricitinib

After 1 year’s worth of hair regrowth among patients treated with baricitinib for severe alopecia areata, treatment withdrawal resulted in a loss of benefit for almost all patients, according to a study.

Responses to baricitinib and dupilumab were notable and similar among patients with moderate to severe atopic dermatitis in a real-world setting, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Deucravacitinib is “very likely to be the best” targeted small-molecule drug for the treatment of systemic lupus erythematosus, according to data published in Arthritis Research & Therapy.

Daily baricitinib, either 4 mg or 2 mg, demonstrates up to 6.5 years of efficacy with low rates of discontinuation due to adverse events in patients with rheumatoid arthritis, according to data published in Rheumatology.

A Janus kinase inhibitor may preserve beta-cell function for children and young adults recently diagnosed with type 1 diabetes, according to findings published in The New England Journal of Medicine.

Patients with juvenile idiopathic arthritis who receive baricitinib demonstrate a “significantly” longer time to disease flare vs. placebo, according to data published in The Lancet.

In a literature review evaluating the findings of two identical phase 3 trials of baricitinib, the oral Janus kinase 1/2 inhibitor was found to be efficacious, safe and “relatively tolerable” in the treatment of severe alopecia areata.

Pooled analysis of two clinical trials found patients with alopecia who did not respond to 2 mg of baricitinib had a significant improvement with a 4 mg dose.